Nanotechnology carriers have become common in pharmaceutical products because of
their benefits to drug delivery, including reduced toxicities and improved efficacy of active …

The delivery of drugs, antigens, and imaging agents benefits from using nanotechnology-
based carriers. The successful translation of nanoformulations to the clinic involves thorough …

Preclinical characterization of novel nanotechnology-based formulations is often challenged
by physicochemical characteristics, sterility/sterilization issues, safety and efficacy. Such …

Preclinical immunotoxicity studies are usually conducted to identify potential causes for
concern before a new drug or a medical device is used in clinical trials. Traditionally, these …

Assorted challenges in physicochemical characterization, sterilization, depyrogenation, and
in the assessment of pharmacology, safety, and efficacy profiles accompany pre-clinical …

Most research on the toxicology of nanomaterials has focused on the effects of nanoparticles
that enter the body accidentally. There has been much less research on the toxicology of …

Nanoparticle immunogenicity and antigenicity have been under investigation for many
years. During the past decade, significant progress has been made in understanding what …

Clear benefits of using engineered nanoparticles for biomedical applications are often
challenged by concerns about the safety of these materials. Since the main job of the …

Abstract Evaluation of the immunomodulatory potentials of nanomaterials is essential for
developing safe and consumer‐friendly nanotechnology. Various nanomaterials interact …

Pharmaceutical products can activate immune cells, suppress their function, or change the
immune responses to traditional immunologically active agonists such as those present in …